Coagulation markers predict survival in cancer patients

Thrombosis and Haemostasis

Volumn 88, Issue 5, 2002, Pages 745-749

  Beer, Juerg Hans ^a   Haeberli, A ^a   Vogt, A ^a   Woodtli, K ^a   Henkel, E ^a   Furrer, Th ^a   Fey, M F ^a  

^a Kantonsspital Baden   (Switzerland)

Author keywords

Coagulation; Fibrin; Fibrinolysis; Thrombin; Tumor markers

Indexed keywords

ALKALINE PHOSPHATASE; ANTICOAGULANT AGENT; CREATININE; D DIMER; FIBRIN MONOMER; FIBRINOPEPTIDE A; LACTATE DEHYDROGENASE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TUMOR MARKER; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; BIOLOGICAL MARKER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEPTIDE HYDROLASE;

ADENOCARCINOMA; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASSAY; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL OBSERVATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ACTIVITY; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; THROMBOEMBOLISM; BLOOD; CASE CONTROL STUDY; FEMALE; MALE; NEOPLASM; PREDICTION AND FORECASTING; PROGNOSIS; RISK; SURVIVAL; SURVIVAL RATE;

ANTITHROMBIN III; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; NEOPLASMS; ODDS RATIO; PEPTIDE HYDROLASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0036846579     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613296     Document Type: Article

References (23)

1. De Moerloose P. D-dimer assays for the exclusion of venous thromboembolism which test for which diagnostic strategy. Thromb Haemost 2000; 83: 180-1.
2. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. British J of Haematology 1996; 92: 479-85.
3. Mombelli G, Im Hof V, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984; 69: 684-9.
4. Trousseau A. Phlegmasia alba dolens. Clinique Médicale de l'Hôtel-Dieux de Paris, 3rd ed, J-B Ballière et fils, Paris 1865: 654-712.
5. Kempin SJ. Hemostatic defects in cancer patients. Cancer Investigation 1997; 15: 23-36.
6. Edwards CN, Warren J, Armstrong L, Donnelly PK. D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Brit J of Surgery 1993; 1404-5.
7. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RCN. Tissue factor expression correlates with histological grade in human pancreatic cancer. Brit J of Surgery 1995; 82: 1101-4.
8. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-5.
9. Shoji M, Hancock WW, Keisuke A, Micko C, Casper KA, Baine RM, et al. Activation of coagulation and angiogenesis in cancer (Immunohistochemical Localization in Situ of Clotting Proteins and Vascular Endothelial Growth Factor in Human Cancer). Am J Pathol 1998; 152: 399-411.
10. Verheul HMW, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK et al. Platelet and Coagulation Activation with Vascular Endothelial Growth Factor Generation in Soft Tissue Sarcomas. Clin Cancer Res 2000; 6: 166-71.
11. Tripodi A, Cattaneo M, Molteni M, Cesana BM, Mannucci PM. Changes of prothrombin fragment 1+2 (F1+2) as a function of increasing intensity of oral anticoagulation. Thromb Haemost 1998; 79: 571-3.
12. Bottasso B, Mari D, Coppola R, Santoro N, Vaglini M. Hypercoagulability and hyperfibrinolysis in patients with melanoma. Thromb Research 1996; 81: 345-52.
13. Buccheri G, Ferrigno D, Ginardi C, Zuliani. Haemostatic abnormalities in lung cancer: Prognostic implications. Eur J Cancer 1997; 33: 50-5.
14. Geiser Th, Sturzenegger M, Genewein U, Haeberli A, Beer JH. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998; 29: 1770-7.
15. Smorenburg SM, Hettiarachchi RJK, Vink R, Büller HR. The effects of unfractionated heparin on survival in patients with malignancy - a systematic review. Thromb Haemost 1999; 82: 1600-4.
16. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low molecular heparins vs standard heparin. Lancet 1992; 339: 1476.
17. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000; 342: 1953-8.
18. Mannucci P. Markers of hypercoagulability in cancer patients. Haemostasis 1997; 27: 25-31.
19. Den Ouden M, Ubachs JMH, Stoot JE, van Wersch JW. Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours. Scand J Clin Lab Invest 1998; 58: 555-9.
20. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467-70.
21. Tricerri A, Vangeli M, Errani AR, Guidi L, Canetta M, et al. Plasma thrombin-antithrombin complexes, latent coagulation disorders and metastatic spread in lung cancer: A longitudinal study. Oncology 1996; 53: 455-60.
22. Edgington TS. Activation of the coagulation system in association with neoplasia. J Lab Clin Med 1980; 96: 1-4.
23. Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 1983; 51: 301-7.